Shares are trading at $2.01 a tad above $1.84, the 50 day moving average and quite a bit lower than the 200 day moving average of $2.52. The 50 day moving average was up by +9.38% whereas the 200 day moving average was down $-0.51 or -20.27%. Trading was heavy with 1,543K shares changing hands in the last trading session. Overall, volume was up 26.59% over the stocks normal daily volume.
Investors are feeling more bearish on shares of the company recently if you look at the increase in short interest. The firm had a rise in short interest between August 15, 2017 and August 31, 2017 of 7.56%. Short shares grew from 1,543,186 to 1,659,925 over that timeframe. The days to cover increased to 10.0 and the percentage of shorted shares was 0.08% on August 31.
Here are a few substantial investment firms who have updated their positions. First Allied Advisory Services, Inc. divested its holdings by selling 5,625 shares a decrease of 6.2% in the quarter. First Allied Advisory Services, Inc. claims 85,475 shares worth $203,000. The total value of its holdings decreased 36.2%. Tower Research Capital LLC (trc) trimmed its ownership by shedding 795 shares a decrease of 100.0%. Tower Research Capital LLC (trc) currently owns 0 shares valued at $0. The value of the position overall is down by 100.0%.
Wealthtrust Axiom LLC expanded its position by buying 68,500 shares an increase of 111.4% as of 06/30/2017. Wealthtrust Axiom LLC now holds 130,000 shares with a value of $309,000. The value of the position overall is up by 44.4%. Blackrock Inc. cut its investment by selling 289,129 shares a decrease of 99.2% from 03/31/2017 to 06/30/2017. Blackrock Inc. controls 2,320 shares worth $6,000. The total value of its holdings decreased 99.4%.
Pulmatrix, Inc., launched on September 25, 2013, is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company?s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease..